Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

n/a
Abstract Title:

Helicobacter pylori increases the risk of low-dose aspirin ulcers: A meta-analysis.

Abstract Source:

J Gastroenterol Hepatol. 2018 Nov 8. Epub 2018 Nov 8. PMID: 30408229

Abstract Author(s):

Gino L Sarri, Sam E Grigg, Neville D Yeomans

Article Affiliation:

Gino L Sarri

Abstract:

BACKGROUND AND AIM: Owing to wide-spread use, low-dose aspirin (LDA) produces a substantial amount of peptic ulcer disease. Current guidelines are ambivalent about the need for Helicobacter pylori eradication to protect against LDA ulcers. This study aimed to determine, through meta-analysis, if (and by how much) infection alters the baseline risk of peptic ulcers during LDA therapy.

METHODS: Literature screening was performed in MEDLINE and EMBASE from inception to May 2018. Original studies reporting prevalence or incidence of uncomplicated ulcers in LDA users were included. Ulcer endpoints needed to be specified separately, according to Helicobacter pylori infection status. Meta-analysis was performed in MIX 2.0 Pro.

RESULTS: Ten cross-sectional studies and seven randomized controlled trials were included (n = 5964). The pooled odds ratios (OR) with 95% confidence intervals (CI) for the risk of LDA ulcers in Helicobacter pylori-positive vs. -negative individuals were 1.68 (95%CI 1.40-2.02) and 1.65 (95%CI 1.29-2.08) under fixed- and random-effects models, respectively. Heterogeneity among studies was minimal (I= 26.9%). After adjusting for the protective effects of antisecretory drugs, the OR increased to 1.94 (95%CI 1.54-2.46).

CONCLUSION: This analysis suggests Helicobacter pylori increases the risk of LDA ulcers by almost 70% in a population where some were taking proton pump inhibitors and/or other acid suppressants. Without antisecretory drugs, the risk almost doubles. Clinically, these findings may support the use of a test-and-treat approach to Helicobacter pylori in LDA users, particularly those at higher risk of developing for peptic ulcers.

Study Type : Meta Analysis

Print Options


Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2019 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.